Figure 2.

Hepatitis B virus primary vaccine efficacy in people with HIV infection. Wide ranges of response are seen across reported studies, ranging from 20% to 70%. (Adapted from Rey D, et al. Vaccine. 2000;18:1161–1165; Tedaldi EM, et al. Clin Infect Dis. 2004;38:1478–1484; Overton ET, et al. Clin Infect Dis. 2005;41:1045–1048; Ungulkraiwit P, et al. Southeast Asian J Trop Med Public Health. 2007;38:680–685; Paitoonpong L, et al. Scand J Infect Dis. 2008;40:54–58; Kim HN, et al. Int J STD AIDS. 2008;19:600–604.)^104–109